Susquehanna International Group
TBPH icon

Susquehanna International Group’s Theravance Biopharma TBPH Stock Holding History

Susquehanna International Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.54M Buy
341,579
+319,683
+1,460% +$5.66M ﹤0.01% 4058
2025
Q4 		$410K Buy
21,896
+1,606
+8% +$26.6K ﹤0.01% 9250
2025
Q3 		$296K Sell
20,290
-29,561
-59% -$374K ﹤0.01% 10137
2025
Q2 		$550K Sell
49,851
-28,075
-36% -$273K ﹤0.01% 8952
2025
Q1 		$696K Buy
77,926
+56,534
+264% +$526K ﹤0.01% 8154
2024
Q4 		$201K Buy
21,392
+10,288
+93% +$93.6K ﹤0.01% 10710
2024
Q3 		$89.5K Sell
11,104
-4,095
-27% -$35.5K ﹤0.01% 11117
2024
Q2 		$129K Buy
+15,199
New +$137K ﹤0.01% 10838
2024
Q1 		– Sell
-53,263
Closed -$599K – 13304
2023
Q4 		$599K Buy
53,263
+13,487
+34% +$136K ﹤0.01% 8218
2023
Q3 		$343K Buy
39,776
+746
+2% +$7.2K ﹤0.01% 9064
2023
Q2 		$404K Sell
39,030
-12,282
-24% -$136K ﹤0.01% 8807
2023
Q1 		$557K Sell
51,312
-122,906
-71% -$1.3M ﹤0.01% 8301
2022
Q4 		$1.95M Buy
174,218
+78,636
+82% +$826K ﹤0.01% 4742
2022
Q3 		$969K Buy
95,582
+62,664
+190% +$587K ﹤0.01% 6703
2022
Q2 		$298K Sell
32,918
-32,761
-50% -$302K ﹤0.01% 9582
2022
Q1 		$628K Sell
65,679
-182,782
-74% -$1.79M ﹤0.01% 8340
2021
Q4 		$2.75M Buy
248,461
+54,942
+28% +$479K ﹤0.01% 4809
2021
Q3 		$1.43M Buy
+193,519
New +$2.16M ﹤0.01% 6609
2021
Q1 		– Sell
-11,081
Closed -$211K – 12840
2020
Q4 		$197K Sell
11,081
-25,025
-69% -$449K ﹤0.01% 10052
2020
Q3 		$534K Buy
36,106
+9,419
+35% +$176K ﹤0.01% 7530
2020
Q2 		$560K Buy
26,687
+9,685
+57% +$249K ﹤0.01% 7135
2020
Q1 		$393K Buy
+17,002
New +$426K ﹤0.01% 7450
2019
Q4 		– Sell
-37,065
Closed -$722K – 10617
2019
Q3 		$722K Buy
37,065
+1,119
+3% +$22.6K ﹤0.01% 6443
2019
Q2 		$587K Buy
+35,946
New +$728K ﹤0.01% 6942
2019
Q1 		– Sell
-9,424
Closed -$239K – 9827
2018
Q4 		$241K Buy
+9,424
New +$254K ﹤0.01% 7406
2018
Q1 		– Sell
-30,359
Closed -$846K – 10161
2017
Q4 		$846K Buy
+30,359
New +$898K ﹤0.01% 5570
2017
Q3 		– Sell
-17,564
Closed -$574K – 9607
2017
Q2 		$700K Buy
+17,564
New +$675K ﹤0.01% 5990
2017
Q1 		– Sell
-49,517
Closed -$1.58M – 9927
2016
Q4 		$1.58M Buy
+49,517
New +$1.54M ﹤0.01% 4566
2015
Q4 		– Sell
-20,563
Closed -$226K – 9965
2015
Q3 		$226K Buy
20,563
+5,850
+40% +$74.5K ﹤0.01% 8525
2015
Q2 		$192K Buy
+14,713
New +$228K ﹤0.01% 9318
2015
Q1 		– Sell
-44,531
Closed -$664K – 9925
2014
Q4 		$664K Buy
+44,531
New +$776K ﹤0.01% 6676
2014
Q3 		– Sell
-16,428
Closed -$524K – 9939
2014
Q2 		$524K Buy
+16,428
New +$495K ﹤0.01% 7384

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's TBPH Position: Q1 2026 in Review

Susquehanna International Group increased its Theravance Biopharma (TBPH) stake by 1,460% in Q1 2026, buying an estimated $5.66M and bringing the position to 341,579 shares worth $5.54M. The position accounts for ﹤0.01% of the portfolio, ranked #4058.

Susquehanna International Group first reported a position in TBPH in Q2 2014 and has held it in 32 quarters since. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Susquehanna International Group held 341,579 shares of Theravance Biopharma worth $5.54M as of Q1 2026.
  • Susquehanna International Group bought 319,683 Theravance Biopharma shares in Q1 2026, an estimated $5.66M.
  • Theravance Biopharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4058 holding.
  • Susquehanna International Group first reported a position in Theravance Biopharma in Q2 2014 and has held it in 32 quarters since.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.